Overview
IMNN market data
Price History
IMNN price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.58 Diluted earnings per share over the trailing twelve months.
- Beta
- 2.00 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1.53 – $8.19 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $6.8 · P/B 1.66 · P/S 13.01.
Company news
IMUNON To Present New Data On IMNN-001, DNA-Based Interleukin-12 Immunotherapy For Advanced Ovarian Cancer, At Inaugural AACR Conference On Drug Discovery And DevelopmentBenzinga · Jul 23, 2026, 1:27 PM
Exclusive: Imunon Says Lead Drug Continues To Show Promise in Advanced Ovarian Cancer PatientsBenzinga · Jul 21, 2026, 12:30 PM
EXCLUSIVE: Imunon Says Phase 2 IMNN-001 Data Showed Lower MRD, Higher ctDNA Clearance And Favorable Safety In Frontline Ovarian Cancer; Preliminary Data Reinforces Immunotherapy’s Potential For Success In Currently Recruiting Phase 3 OVATION 3 StudyBenzinga · Jul 21, 2026, 12:30 PM
Imunon Says Jeffrey Church To Retire As Interim CFO Effective July 1, 2026; Appoints Josh Blacher As Interim CFO Effective July 1, 2026Benzinga · Jun 30, 2026, 8:50 PM
8-K filing — Imunon, Inc. (IMNN)SEC EDGAR · Jun 30, 2026, 8:30 PM
IMUNON Receives Independent Data Monitoring Committee Recommended Continuation Of Pivotal Phase 3 OVATION 3 Clinical Trial Of IMNN-001 In Combination With Standard Of Care Neoadjuvant And Adjuvant Chemotherapy In Women With Newly Diagnosed Advanced Ovarian CancerBenzinga · Jun 23, 2026, 12:10 PM
IMUNON Enters Into Definitive Agreements For $10M In Preferred Stock And Secured NotesBenzinga · Jun 4, 2026, 12:10 PM